Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly’s VEGF2-inhibitor failed to meet its primary endpoint of progression-free survival in a Phase III breast cancer study but met the primary endpoint of improved overall survival in an advanced gastric cancer trial.

You may also be interested in...



Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial

Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.

Lilly’s Ramucirumab Makes An Impact In Tough-To-Treat Gastric Cancer, But Will It Be Enough?

The vascular endothelial growth factor inhibitor demonstrated a 1.4 month improvement in overall survival, giving some investors the jitters but encouraging clinician experts, especially given previous targeted drug trial failures.

Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning

The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel